Related Experiment Video

Updated: Jul 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

[Different Prophylaxis Strategies for Central Nervous System Recurrence of Diffuse Large B-Cell Lymphoma]

Shuang Qu1, Li-Sheng Liao1, Yan-Bin Zheng2

  • 1Department of Hematology, Shengli Clinical Medical College of Fujian Medical University Fujian Provincial Hospital, Fuzhou 350001, Fujian Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|October 31, 2024
PubMed
Summary

Lenalidomide demonstrates a trend towards improved progression-free survival and overall survival compared to high-dose methotrexate (HD-MTX) for central nervous system (CNS) prophylaxis in diffuse large B-cell lymphoma (DLBCL) patients. Both strategies show comparable CNS relapse-free survival rates and are well-tolerated with no treatment-related deaths.

Keywords:
diffuse large B-cell lymphoma; central nervous system; prophylaxis

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K
Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype08:49

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

11.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...